IMP3 expression in urothelial carcinomas of the urinary bladder

Turk Patoloji Dergisi/Turkish Journal of Pathology

Volumn 27, Issue 1, 2011, Pages 31-37

  Özkalay Özdemir, Nihal ^a   Şen Türk, Nilay ^a   Düzcan, Ender ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

IMP3; Transitional cell carcinoma; Urinary bladder; Urothelial carcinoma

Indexed keywords

INSULIN LIKE GROWTH FACTOR II MRNA BINDING PROTEIN 3; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM; YOUNG ADULT;

EID: 79551718351     PISSN: 10185615     EISSN: 13095730     Source Type: Journal    
DOI: 10.5146/tjpath.2011.01009     Document Type: Article

References (26)

1. Lopez-Beltran A, Sauter G, Gasser T, Hartmann A, Schmitz-Drager BJ, Helpap B, Ayala AG, Tamboli P, knowles MA, Sidransky D, Cordon-Cardo C, Jones PA, Cairns P, Simon R, Amin MB, Tycynski JE: Infiltrating urothelial carcinoma. In Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds): Tumors of the Genito-Urinary and Male Genital Organs. Lyon, IAR C Press, 2004, 93-109
2. Sengupta S, Blute ML: The management of superficial transitional cell carcinoma of the bladder. Urology 2006, 67: 48-54
3. Li L, Xu H, Spaulding BO, Cheng L, Simon R, Yao JL, di Sant'Agnese PA, Bourne PA, Huang J: Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol 2008, 39:1205-1211
4. Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z: IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 2008, 14:1701-1706
5. Habuchi T, Marberger M, Droller MJ, Hemstreet GP 3rd, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB: Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005, 66:64-74 (Pubitemid 43049609)
6. Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006, 27: 361-373
7. Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, Theodorescu D: Profiling the evolution of human metastatic bladder cancer. Cancer Res 2004, 64: 7813-7821
8. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC: A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999, 19: 1262-1270
9. Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G, Gress TM: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999, 88:95-99
10. Müeller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Büchler M, Beger HG, Vila MR, Adler G, Gress TM: Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997, 14:2729-2733
11. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K: KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005, 29: 188-195
12. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol 2009, 20: 149-157
13. Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH, Hsu HC: RNA -binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 2008, 48:1118-1127
14. Riener MO, Fritzsche FR, Clavien PA, Pestalozzi BC, Probst-Hensch N, Jochum W, Kristiansen G: IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol 2009, 40:1377-1383
15. Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H: IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 2008, 21: 431-437
16. Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z: An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol 2009, 33: 521-525
17. Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG: L523S, an RNA -binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003, 88: 887-894
18. Jeng YM, Wang TH, Lu SH, Yuan RH, Hsu HC: Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg 2009, 96: 66-73
19. Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM: Diffuse expression of RNA -binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 2009, 16: 1711-1719
20. Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB: IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 2009, 22:469-475
21. Yaniv K, Yisraeli JK: The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 2002, 287: 49-54
22. Righi A, Zhang S, Jin L, Scheithauer BW, Kovacs K, Kovacs G, Goth MI, Korbonits M, Lloyd RV: Analysis of IMP3 expression in normal and neoplastic human pituitary tissues. Endocr Pathol 2010, 21:25-31
23. Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF: Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994, 151: 31-35
24. Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, Groshen S, Lieskovsky G, Boyd SD, Skinner DG: Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995, 76:833-839
25. Herr HW, Sogani PC: Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001, 166: 1296-1299
26. Stockle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R: Radical cystectomy-often too late? Eur Urol 1987, 13: 361-367